The therapy of autoimmune disease by ES cell-derived myeloid cells (ES-ML)

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K19493
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Neurology
• Research Institution: Kumamoto University
• Principal Investigator: Ikeda Tokunori 熊本大学, 医学部附属病院, 助教 (00613530)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: ES細胞由来ミエロイド細胞 / iPS細胞由来ミエロイド細胞 / 実験的自己免疫性脳脊髄炎 / 免疫抑制性マクロファージ

Outline of Final Research Achievements

I investigated whether or not ES or iPS cell derived myeloid cell (ES-, iPS-ML) had the immunoinhibitory function for experimental autoimmune encephalomyelitis (EAE). The administration of TARIL, which function immuno-inhibitory molecule, gene transferred ES-ML (ES-ML-TRAIL) improved the clinical symptoms of EAE. However, a lot of ES-ML-TRAIL were needed to ameliorate the state of EAE. On the other hand, ES- or iPS-ML functioned like a macrophage, and expressed immunoinhibitory macrophage’s marker, CD163 and CD206. These results suggested the possibility that the application of ES- or iPS-ML was appropriate in the diseases that macrophage’s function were available, but autoimmune diseases.

Free Research Field

Neurology